Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jul;41(7):879-880.
doi: 10.1038/s41401-020-0426-2. Epub 2020 May 28.

Nanomedicine and cancer immunotherapy

Hai-Jun Yu  1 , Bruno G De Geest  2
Affiliations
Editorial

Nanomedicine and cancer immunotherapy

Hai-Jun Yu et al. Acta Pharmacol Sin. 2020 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Van Herck S, De Geest BG. Nanomedicine-mediated altering of the pharmacokinetic profile of small molecule cancer immunotherapeutics. Acta Pharmacol Sin. 2020;41:881–94. doi: 10.1038/s41401-020-0425-3. - DOI - PMC - PubMed
    1. Qi FL, Wang MF, Li BZ, Lu ZF, Nie GJ, Li SP. Reversal of the immunosuppressive tumor microenvironment by nanoparticle-based activation of immune-associated cells. Acta Pharmacol Sin. 2020;41:895–901. doi: 10.1038/s41401-020-0423-5. - DOI - PMC - PubMed
    1. Yin WM, Li YW, Gu YQ, Luo M. Nanoengineered targeting strategy for cancer immunotherapy. Acta Pharmacol Sin. 2020;41:902–10. doi: 10.1038/s41401-020-0417-3. - DOI - PMC - PubMed
    1. Yang F, Shi K, Jia YP, Hao Y, Peng JR, Qian ZY. Advanced biomaterials for cancer immunotherapy. Acta Pharmacol Sin. 2020;41:911–27. doi: 10.1038/s41401-020-0372-z. - DOI - PMC - PubMed
    1. Zhong XF, Sun X. Nanomedicines based on nanoscale metal-organic frameworks for cancer immunotherapy. Acta Pharmacol Sin. 2020;41:928–35. doi: 10.1038/s41401-020-0414-6. - DOI - PMC - PubMed

Publication types

Substances